None listed
Conditions
Interventions
Intervention1: Cysteamine, Alpha Arbutin, Niacinamide, Tamarindus Indica Cream: The Product is applied on melasma patches on face once in night for the period of 112 days.
Control Intervention1: Nil:
Sponsors
Glenmark Pharmaceuticals Ltd.
Eligibility
Inclusion criteria
Inclusion criteria: 1. Indian Male and Female subjects 2. Healthy subjects 3. Skin is healthy on the studied anatomic unit 4. Human subjects with melasma
Exclusion criteria
Exclusion criteria: 1. Being pregnant or breastfeeding or having stopped to breastfeed in the past three months. 2. Having refused to give her assent by not signing the consent form. 3. Taking part in another study liable to interfere with this study. 4. Being insulin-dependent diabetic or non-insulin-dependent diabetic with a recent therapy (less than 6 months) 5. Having progressive asthma. 6. Being epileptic. 7. Having non stabilized thyroid problems (requirement of a stabilized treatment for at least 6 months) 8. Having cutaneous hypersensitivity 9. Having a diagnosed or highly probable allergy to one or several compounds of cosmetic products. 10. Following a chronic medicinal treatment comprising any of the following products: aspirin-based products, anti-inflammatories, anti-histamines, corticotherapy, taken by general or local routes (the only medication permitted is paracetamol) 11. Having consumed caffeine-based products (coffee, cola, tea …), alcohol, highly spiced foods and/or smoked in the two hours preceding the measurements. 12. Having undergone a surgery requiring a general anaesthetic of more than one hour in the past 6 months. 13. Having changed her cosmetic habits in the 14 days preceding the start of the study on the studied anatomic unit 14. Having applied a cosmetic product (included make-up) or skin care product on the studied areas the day of the study (only face cleaned with water is accepted)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Reduction in melasmaTimepoint: Baseline, 28 days, 56 Days, 84 Days, 112 Days | — |
Secondary
| Measure | Time frame |
|---|---|
| Change in pigmentation, change in MELASQOL (quality of lifestyle) related to melasma, Cosmetic AcceptabilityTimepoint: Baseline, 28 days, 56 Days, 84 Days, 112 Days | — |
Countries
India
Contacts
Public ContactDr Mohit Lalvani
MASCOT-SPINCONTROL India Pvt. Ltd.
Outcome results
None listed